Hematologic Disorders
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Visual and Auditory Distraction for the Relief of Pain and Anxiety
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device